0000000000780940

AUTHOR

A. Chiesa

showing 3 related works from this author

Retreatment with interferon plus ribavirin of chronic hepatitis C non-responders to interferon monotherapy: a meta-analysis of individual patient dat…

2002

Background and aims: Retreatment with a combination of α interferon (IFN) plus ribavirin of patients with chronic hepatitis C who did not respond to IFN monotherapy has not been assessed in large controlled studies. Methods: To assess the effectiveness and tolerability of IFN/ribavirin retreatment of non-responders to IFN and to identify predictors of complete (biochemical and virological) sustained response, we performed a meta-analysis of individual data on 581 patients from 10 centres. Retreatment with various IFN schedules (mean total dose 544 mega units) and a fixed ribavirin dose (1000–1200 mg/daily depending on body weight) was given for 24–60 (mean 39.5) weeks. Results: Biochemical …

HCV interferon ribavirinAdultMalemedicine.medical_specialtyCombination therapymedicine.medical_treatmentAlpha interferonGastroenterologyAntiviral AgentsDrug Administration Schedulechemistry.chemical_compoundDrug TherapyInternal medicineRibavirinmedicineHumansImmunologic FactorsTreatment FailureChronicAdverse effectChemotherapyAdult; Antiviral Agents; Chi-Square Distribution; Drug Administration Schedule; Drug Therapy; Combination; Female; Hepatitis C; Chronic; Humans; Immunologic Factors; Interferon-alpha; Logistic Models; Male; Middle Aged; Ribavirin; Treatment Failure; gamma-GlutamyltransferaseChi-Square Distributionbusiness.industryRibavirinLiver DiseaseGastroenterologyInterferon-alphaHepatitis Cgamma-GlutamyltransferaseHepatitis C ChronicMiddle Agedmedicine.diseaseHepatitis CConfidence intervalhumanitiesSurgeryLogistic ModelschemistryTolerabilityCombinationDrug Therapy CombinationFemalebusiness
researchProduct

Predicting Mortality Risk in Patients With Compensated HCV-Induced Cirrhosis: A Long-Term Prospective Study

2009

OBJECTIVES: The identification of prognostic factors associated with mortality is crucial in any clinical setting. METHODS: We enrolled in a prospective study 352 patients with compensated hepatitis C virus (HCV)-induced cirrhosis, consecutively observed between 1989 and 1992. At entry, patients underwent upper endoscopy to detect esophageal varices, and were then surveilled by serial clinical and ultrasonographic examination. The model for end-stage liver disease (MELD) score was calculated with information collected at enrollment. Baseline predictors and intercurrent events associated with mortality were assessed using the Cox regression model. RESULTS: During a median follow-up of 14.4 y…

AdultLiver CirrhosisMalemedicine.medical_specialtyTime FactorsCirrhosisBiopsy Fine-NeedleKaplan-Meier EstimateEsophageal and Gastric VaricesAntiviral AgentsRisk AssessmentSeverity of Illness IndexGastroenterologyCohort StudiesPredictive Value of TestsCause of DeathInternal medicineEpidemiologyConfidence IntervalsmedicineHumansProspective StudiesRisk factorProspective cohort studyAgedProbabilityProportional Hazards ModelsCause of deathSettore MED/12 - GastroenterologiaHepatologybusiness.industryGastroenterologyInterferon-alphavirus diseasesHepatitis CHepatitis C ChronicMiddle Agedmedicine.diseaseImmunohistochemistrySurvival Analysisliver cirrhosis natural historyDisease ProgressionFemalebusinessRisk assessmentLiver FailureFollow-Up StudiesCohort studyThe American Journal of Gastroenterology
researchProduct

Adherence issues related to sublingual immunotherapy as perceived by allergists.

2010

Silvia Scurati1, Franco Frati1, Gianni Passalacqua2, Paola Puccinelli1, Cecile Hilaire1, Cristoforo Incorvaia3, Italian Study Group on SLIT Compliance 1Scientific and Medical Department, Stallergenes, Milan, Italy; 2Allergy and Respiratory Diseases, Department of Internal Medicine, Genoa; 3Allergy/Pulmonary Rehabilitation, ICP Hospital, Milan, ItalyObjectives: Sublingual immunotherapy (SLIT) is a viable alternative to subcutaneous immunotherapy to treat allergic rhinitis and asthma, and is widely used in clinical practice in many European countries. The clinical efficacy of SLIT has been established in a number of clinical trials and meta-analyses. However, because SLIT is self-administered…

medicine.medical_specialtyPathologygenetic structuresefficacyAlternative medicineMedicine (miscellaneous)Adherence Cost Efficacy Side effects Sublingual immunotherapySettore MED/10 - Malattie Dell'Apparato Respiratoriosublingual immunotherapyALLERGENcostmedicineSubcutaneous immunotherapySublingual immunotherapyadherenceClinical efficacyIntensive care medicinePharmacology Toxicology and Pharmaceutics (miscellaneous)sublingual immunoterapyOriginal ResearchAsthmaAEROALLERGENSadherence; sublingual immunotherapy; efficacy; cost; side effectsbusiness.industryHealth Policymedicine.diseaseSliteye diseasesClinical trialside effectsPatient Preference and Adherenceadherence; sublingual immunoterapy; efficacy; cost; side effects.immunotherapysense organsAllergistsADHERENCE TO TREATMENTbusinessSocial Sciences (miscellaneous)
researchProduct